Finanzen von IRadimed Corp (IRMD)IRMDIRadimed Corp

IRADIMED CORPORATION (IRMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is MRI Compatible Patient Vital Signs Monitoring Systems, accounting for 32.6% of total sales, equivalent to $6.67M. Other significant revenue streams include MRI Compatible IV Infusion Pump Systems and Disposables, services and other. Understanding this composition is critical for investors evaluating how IRMD navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, IRADIMED CORPORATION maintains a gross margin of 74.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 31.23%, while the net margin is 25.50%. These profitability ratios, combined with a Return on Equity (ROE) of 23.52%, provide a clear picture of how effectively IRMD converts its operational activities into shareholder value.

In the context of the broader market, IRMD competes directly with industry leaders such as STAA and NNNN. With a market capitalization of $1.10B, it holds a significant position in the sector. When comparing efficiency, IRMD's gross margin of 74.07% stands against STAA's 74.55% and NNNN's 87.24%. Such benchmarking helps identify whether IRADIMED CORPORATION is trading at a premium or discount relative to its financial performance.

IRadimed has shown stable revenue growth, with Q2 2026 revenue reported at $20.5 million, a slight increase of 0.5% year-over-year. However, the net income for Q2 2026 was $5.2 million, reflecting a decrease from previous quarters, which raises concerns about future profitability.